Analysis argues Novo Nordisk shares trade 59% below fair value
A Simply Wall St valuation model pegs Novo Nordisk as deeply undervalued based on continued GLP-1 franchise growth.
TR
By Tom Reyes · Markets Editor
Sep 16 17:05 ETSource: simplywall.st
The wire
- 01A published valuation analysis estimates Novo Nordisk stock could be 59% undervalued on GLP-1 growth assumptions.
- 02The call lands as investors debate whether Novo can defend obesity market share.
- 03Model assumptions are unverified and the estimate depends on future GLP-1 sales trajectory.
From the source
Read at news.google.comNovo Nordisk (NVO) Could Be 59% Undervalued On Its GLP 1 Growth Narrative